+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06621212

Phase 2 Study of Mitoxantrone Hydrochloride Liposome, Cytarabine, and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Led by First Affiliated Hospital of Zhejiang University · Updated on 2025-09-16

72

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of a combination treatment using mitoxantrone hydrochloride liposome injection, standard-dose cytarabine, and venetoclax MAV for adults with relapsed or refractory acute myeloid leukemia RR AML. This phase 2, multi-center study recognizes that there is no established standard treatment for RR AML and aims to build on previous research suggesting that mitoxantrone may target leukemia stem cells resistant to venetoclax. Participants will receive the MAV treatment regimen consisting of 30 mgm2 mitoxantrone hydrochloride liposome on day 1, 100 mgm2 cytarabine daily on days 1 through 7, and venetoclax given with a dose escalation from 100 mg on day 2 up to 400 mg on days 4 through 8. Each treatment cycle lasts 4 weeks, with up to two cycles planned. Patients showing response after the first cycle may receive a second similar induction cycle. Those achieving complete remission may be recommended for stem cell transplant or receive adapted consolidation therapy based on age and fitness. Throughout the study, participants will undergo regular laboratory tests including bone marrow and blood samples to monitor treatment effects. The main outcome measured is the composite complete remission rate after up to two 28-day cycles. Additional outcomes include overall response, survival rates, and safety assessments up to 12 months. Close monitoring of side effects and treatment tolerability will occur from the first dose through 28 days after treatment ends, with the total duration of participation depending on response and treatment cycles completed.

CONDITIONS

Brief Title

Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML

Research Team

J

Jie Jin, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here